

#### **Laboratory Service Report**

### 1-800-533-1710

Patient Name SAMPLEREPORT,WARFP A	Patient ID SA00060520	<b>Age</b> 47	Gender F	Order # SA00060520	
Ordering Phys CLIENT,CLIENT		·		<b>DOB</b> 06/10/1966	
Client Order # SA00060520	Account Information			Report Notes	
<b>Collected</b> 07/31/2013 00:00	C7028846-DLMP Roch 3050 Superior Drive	ester			
<b>Printed</b> 08/13/2013 08:54	Rochester, MN 55901	Rochester, MN 55901			

Test Flag Results Unit Value Site\*

Warfarin Sensitivity Genotype

**RECEIVED:** 08/01/2013 14:41 **REPORTED:** 08/12/2013 16:53

Warfarin Sensitivity, Genotype Warfarin Sens Phenotype Interp

MCR

Predicted high warfarin sensitivity. This patient has a genotype associated with high warfarin sensitivity. A significant dose decrease may be required to maintain optimal INR. See link to the FDA for dosing information. Cytochrome P450 2C9 (CYP2C9) metabolizes warfarin and Vitamin K Epoxide Reductase Complex, subunit 1 (VKORC1) is the target of warfarin therapy. The combined genotype can be used to predict an individual's response to warfarin therapy. Bidirectional DNA sequence analysis was used to test for the presence of variants in exons 3, 5, and 7 of the CYP2C9 gene as well as in VKORC1's distal promoter. These sequencing reactions detect the presence of CYP2C9 430C>T (\*2), 818delA (\*6), 1075A>C (\*3), 1076T>C (\*4), 1080C>G (\*5), and VKORC1 -1639G>A. This sequencing assay will not detect all the known mutations that result in decreased or inactive CYP2C9 or VKORC1. Rare polymorphisms could interfere with test results. Absence of a detectable gene mutation or polymorphism does not rule out the possibility that a patient has an intermediate or high sensitivity phenotype due to the presence of an undetected polymorphism or due to drug-drug interactions. Laboratory developed test.

CYP2C9 Star Alleles/VKORC1 Genotype

2/3 G/A

MCR

Initial drug dosing recommendations for this CYP2C9/VKORC1 genotype is available in Table 5 of the drug label, located online at:

http://www.accessdata.fda.gov/drugsatfda\_docs/label/2010/009 218s108lbl.pdf.

Numerous drugs have been reported to alter the warfarin dosing requirements for patients. The warfarin drug labeling also contains information regarding numerous potential drug interactions and endogenous factors that may impact dosing.

For a full description of CYP2C9 alleles, see: http://www.cypalleles.ki.se/cyp2c9.htm.

CYP2C9 430C>T(\*2) C/T
CYP2C9 818delA(\*6) A/A
CYP2C9 1075A>C(\*3) A/C

MCR MCR MCR

\*\*\*Performing Site Legend on Last Page of Report\*\*\*

Patient Name	Collection Date and Time	Report Status
SAMPLEREPORT, WARFP A	07/31/2013 00:00	Final
Page 1 of 2		>> Continued on Next Page >>

<sup>\*</sup> Report times for Mayo performed tests are CST/CDT



# **Laboratory Service Report**

## 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #	
SAMPLEREPORT,WARFP A	SA00060520	47	F	SA00060520	
Ordering Phys				DOB	
CLIENT,CLIENT				06/10/1966	
Client Order #	Account Information			Report Notes	
SA00060520				-	
Collected	C7028846-DLMP Roch	nester			
07/31/2013 00:00	3050 Superior Drive	3050 Superior Drive			
Printed	Rochester, MN 55901				
08/13/2013 08:54					

Test	Flag	Results	Unit	Reference Value	Perform Site*
CYP2C9 1076T>C(*4)		T/T			MCR
CYP2C9 1080C>G(*5)		C/C			MCR
VKORC1 -1639G>A		G/A			MCR
Warfarin Sens Genotype Interp					MCR
This patient has two copies	of alleles	encoding CYP2C9			
protein with reduced activit	y. The pat	ient also has one			
copy of VKORC1 with normal a	activity and	d one with reduced			
expression. Additional desc	criptions of	the effects of the			
star alleles and variations	on CYP2C9 a	and VKORC1 function			
are found in the Mayo Test (	Catalog				
(http://www.mayomedicallabor	ratories.com	n/test-catalog/).			
Warfarin Sensitivity Reviewed b	У	Jamie Bruflat			MCR
Warfarin Sensitivity Genotyping		Performed			MCR

### \* Performing Site:

MCR Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.
--	--

Patient Name	Collection Date and Time	Report Status
SAMPLEREPORT,WARFP A	07/31/2013 00:00	Final
Page 2 of 2		** End of Report **

<sup>\*</sup> Report times for Mayo performed tests are CST/CDT